Portal de Periódicos da CAPES

Reducing irinotecan‐associated diarrhea in children

2007; Wiley; Volume: 50; Issue: 2 Linguagem: Inglês

10.1002/pbc.21280

1545-5017

Lars M. Wagner, Kristine R. Crews, Clinton F. Stewart, Carlos Rodríguez‐Galindo, René McNall-Knapp, Karen Albritton, Alberto S. Pappo, Wayne L. Furman,

Lung Cancer Research Studies

Abstract Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan. Pediatr Blood Cancer 2008; 50:201–207. © 2007 Wiley‐Liss, Inc.